Company Metrics

• 101.96 P/E
• 30.45 P/S
• 10.32 P/B
• -0.384 EPS
• 830.78% Cash ROIC
• 5.89 Cash Ratio
• 0 / 0% Dividend
• 133,237.00 Avg. Vol.
• 32.93M Shares
• 371.1M Market Cap.

Company Description

Osiris Therapeutics, Inc., a stem cell therapeutic company, focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States and internationally. Its lead biologic drug candidate includes Prochymal, which is in Phase 3 clinical trials for the treatment of acute and steroid refractory graft versus host disease (GvHD) and Crohn's disease, as well as for the repair of gastrointestinal injury resulting from radiation exposure. The company is also developing its Prochymal drug candidate for the repair of heart tissue following a heart attack, and for the protection of pancreatic islet cells in patients with type 1 diabetes. In addition, it is developing Chondrogen, a biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. Additionally, the company focuses on developing biologic products for use in surgical procedures. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for developing Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for the distribution of Prochymal for GvHD in Japan. Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, Maryland.
less

Osiris Therapeutics, Inc., a stem cell therapeutic company, focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States and internationally. Its lead biologic drug candidate includes Prochymal, which is in Phase 3 clinical trials for the treatment of acute and steroid refractory graft versus host disease (G...
more

News